Background/Aims: As a major inflammatory molecule released from mast cell activation, histamine has been reported to regulate TLRs expression and cytokine production in inflammatory cells present in the microenvironment. In this study, we determined the ability of histamine to modulate TLRs expression and cytokine production in mast cells. Methods: HMC-1 and P815 cells were exposed to various concentrations of histamine in the presence or absence of histamine antagonist for 2, 6 or 16 h. The effect of histamine on the expression of TLR3 protein and mRNA was analyzed by flow cytometry、 RT-PCR and immunofluorescent microscopy. Furthermore,we also examined the effect of histamine on the secretion of MCP-1 and IL-13 from mast cells by ELISA. Results: The amplification of TLR3 mRNA and protein expression in mast cells was observed after incubation with histamine, which was accompanied by increasing secretion of IL-13 and MCP-1 via H1 receptor. The signaling pathways of PI3K/ Akt and Erk1/2/MAPK contributed to these induction effects. Conclusion: These results demonstrate that histamine up-regulates the expression of TLR3 and secretion of IL-13 and MCP-1 in mast cells, thus identifying a new mechanism for the histamine inducing allergic response.
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Introduction
Mast cells have an essential role in allergic diseases, and have shown to be essential in regulating host defense, innate and acquired immunity, homeostatic responses, and immuneregulation [1] [2] [3] [4] . Activation of mast cells via cross-linking of membrane bound IgE induces a release of potent mediators including histamine. Besides its pro-inflammatory effect, histamine exerts other regulatory functions by modulating the activity of T cells, monocytes, macrophages, eosinophils [5] and basophils [6] . In addition, histamine can inhibit further degranulation of mast cells by acting on H4 receptors [7] , which suggests it is insolvent in the feed-back regulation of immunological responses.
Recently, mast cell have also been found essential in the defense against bacteria and viruses via the Toll-like receptors (TLRs), which are a family of receptors that have the ability to recognize a wide variety of pathogen-associated molecular patterns (PAMP) [8] [9] [10] [11] . Until now, a total of 10 human TLRs including TLR1-10 and 13 mouse TLRs including TLR1-9 and TLR11-13 have been discovered [8] . Also, there is a research in progress on the ligands and some functional interactions of these receptors. For example, peptidoglycan stimulation of bone marrow-derived mast cells via TLR2 leads to both cytokine release and degranulation [12] . TLR3 can recognize viral double-stranded RNA, which lead to immune responses characterized by the production of type I interferons and proinflammatory cytokines [13] . Moreover, TLR3 enhances eosinophils infiltration in experimental allergic conjunctivitis [14] and contact dermatitis [15] .
Since TLRs are known as receptors for micro-organism pathogens that are highly expressed in mast cells, histamine has been reported to regulate TLR expression and cytokine production in inflammatory cells [16] [17] [18] [19] ; to enhance the secretion of Th2 cytokines such as IL-4, IL-5, IL-10 and IL-13; and to inhibit the production of Th1 cytokines such as IL-2 and IFN-γ [20] , we anticipated that histamine ought to regulate TLR expression and cytokine production in mast cells, and thus participate in the pathogenies of allergic diseases. In the present study, we found that histamine was able to upregulate expressions of TLR3, and IL-13 and MCP-1 released from human and mouse mast cells lines.
Materials and Methods
Reagents and cells HMC-1 cell line was kindly provided by Dr. Zuotao Zhao from the First Hospital, Peking University, Beijing. P815 cell line was purchased from American Type Culture Collection (Manassas, VA, USA). Human and mouse MCP-1 and IL-13 ELISA kits were bought from R&D (Minneapolis, MN). Tissue culture reagents including Dulbecco's modified Eagle's medium (DMEM), RPMI 1640 media, HEPES and Fetal bovine serum (FBS) were obtained from GibcoBRL (Carlsbad, CA, USA). Histamine, terfendine and cimetidine were purchased from Sigma-Aldrich (St. Louis, MO, USA). TRIzol Reagent and SYBR Green I Stain were from Invitrogen (Carlsbad, CA, USA). ExScript TM RT reagent kit and SYBR ® Premix Ex Taq TM (perfect real time) were from TaKaRa (DaLian, China). FITC-conjugated rat monoclonal antibody against mouse TLR3, PE-conjugated mouse monoclonal antibody against human TLR3, PE-conjugated mouse isotype control and FITC-conjugated rat isotype control were from Immugenex Corp (Los Angeles, CA, USA). Monoclonal antibodies that detect activating phosphorylations or unphosphorylations of Akt (Ser473), and ERK-1/2 (Thr202/Tyr204) were from Cell Signaling Technology (Beverly, ME, USA). LY294002, U0126, SB203580 and AG490 were purchased from Promega (Madison, WI, USA). Poly (I:C) was from the Invivogen (San Diego, CA, USA). Most of other reagents such as salt and buffer components were analytical grade and were obtained from Sigma-Aldrich (St. Louis, MO, USA).
Cell culture
All cells were cultured in 75-cm 2 tissue culture flasks in a humidified atmosphere containing 5%CO 2 /95% air at 37ºC. HMC-1 cells were maintained in RPMI 1640 media supplemented with 10 mM HEPES, gentamycin 50 μg/ml, 2 mM L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin and 10% heat inactivated fetal bovine serum; P815 cells were cultured with ATCC complete growth medium including DMEM supplemented with 4 mM L-glutamine, 1.5 mg/ml sodium bicarbonate, 4.5 mg/ml glucose, 10 % FBS, 100 U/ml penicillin and 100 μg/ml streptomycin.
Cell challenge
For the challenge experiments, mast cell lines HMC-1 and P815 at 1 × 10 6 cells/ml concentration were transferred into 6-well plastic culture plates, cultured with the serum-free basal medium for 16 h and washed twice before challenge. Cells were then exposed to various concentrations of histamine (0. 01 -10.0 μg/ml) for 2, 6 or 16 h. After centrifugation, culture supernatants were collected and stored at -80
• C until use, and cells were harvested for immunofluorescence and real time PCR.
For certain experiments, cells were preincubated with 1.0 μg/ml of terfenadine or 10 μg/ml cimetidine for 1 h before addition of histamine. At 6h or 16 h following incubation, the culture plates were centrifuged at 450 g for 10 min at 25 °C. The cells were then harvested for immunofluorescence and real time PCR. The culture supernatants were collected and stored at -80 °C for further use.
To determine if histamine affects poly (I:C) induced MCP-1 and IL-13 release, cells were preincubated with 0.1 μg/ml of histamine for 16 h before adding 25μg/ml poly (I:C) for 16 h. The culture supernatants were collected and stored at -80 °C for further use.
For cell signaling experiments, cultured cells at a density of 1.0 x 10 6 cells/ml were washed twice with the serum-free basal medium, and then were treated with the inhibitors of cell signaling pathways, including U0126 (5 µM), SB203580 (20 µM), LY294002 (20 µM) and AG490 (40 µM) for 30 min before being challenged with histamine (10 µg/ml) for 30 min, 2 h, and 6h. The culture supernatants were then collected and stored at -80°C, and cells were collected for immunofluorescence analysis or ELISA and cell signal analysis. The concentrations of inhibitors were chosen according to previous study [18] .
Enzyme linked immunosorbent assay (ELISA) for cytokine secretion MCP-1 and IL-13 were measured using ELISA kits according to the manufacturer's instruction. . Each measurement of a sample was conducted in duplicate.
Immunoblotting
After cells were stimulated with histamine (or medium alone) for 0.5 h, 2 h, 6 h and 16 h, cells were washed twice with ice-cold PBS and then lysed for 30 min in 0.1 ml lysis buffer: 20 mM HEPES, pH 7.3, 1 % Triton X-100, 10 % glycerol, 12.5 mM sodium pyrophosphate, 10 mM sodium orthovanadate, 50 mM sodium fluoride, 1 mM phenylmethylsulfonyl fluoride, 30 μg/ml leupeptin, 30 μg/ml aprotinin, and 25 mM pnitrophenyl phosphate. Cell debris was removed by centrifugation of the lysate at 13, 000 g for 10 min. The supernatants were mixed with equal volumes of 5×sodium dodecyl sulphate sample buffer and heated to 100
• C for 10 min. An equal volume of sample was then fractionated by SDS-PAGE on a 10 % acrylamide gel and transferred onto a polyvinylidene difluoride (PVDF) membrane with a Bio-Rad semidry transfer Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry system, according to the manufacturer's instructions. After blocking non-specific binging sites with 5 % BSA in TBS/Tween for 1 h, membranes were probed with anti-Akt (Ser473), anti-ERK-1/2 (Thr202/Tyr204) or anti-phospho-antibodies overnight followed by incubated with HRP-conjugated secondary antibodies.
Immunoreactive bands were visualized using enhanced chemiluminescence reagents (Pierce, Rockford, IL) according to the manufacturer's protocol. Densitometry analysis of immunoblots was carried out using ScionImage software. The relative levels of phospho-Akt (Ser473) or phospho-ERK-1/2 (Thr202/Tyr204) were expressed as the ratio to Akt (Ser473) or ERK-1/2 (Thr202/Tyr204).
Statistical analysis
Data were expressed as mean ± SEM for four independent experiments. Where analysis of variance indicated significant differences between groups with ANOVA, for the preplanned comparisons of interest, Student's t-test was applied utilizing the SPSS19.0 version. P < 0.05 was considered statistically significant.
Results

Expression of TLR3 in mast cells
RT-PCR, FACS analysis and immunofluorescent cell staining were employed to examine the expression of TLR3 in HMC-1 and P815 cells. The results showed that both human and mouse mast cells express TLR3 mRNA (Fig. 1A) and protein ( Fig. 1B and 1C) .
Influence of histamine on the expression of TLR3 mRNA in mast cells
Quantitative real-time PCR results showed that histamine induced the up-regulation of expression of TLR3 mRNA. Histamine at the concentrations of 0.1, 1.0 and 10 μg/ml induced a dose-dependent upregulation of TLR3 mRNA expression following a 6 h incubation period. The maximum induced expression of TLR3 mRNA was 5.1 and 6.0 fold over baseline control in HMC-1 ( Fig. 2A) and P815 (Fig. 2B ) cells, respectively.
Furthermore, the time course study showed that upregulated TLR3 mRNA expression was observed at 2 h and reached almost baseline level at 6 h following incubation, both in HMC-1 ( Fig. 2A) and P815 (Fig. 2B ) cells. 
Influence of histamine on expression of TLR3 on mast cells
In HMC-1 cells, induced upregulation of TLR3 was observed after 6 h incubation with 1.0 and 10 μg/ml histamine, and after 16 h incubation with 0.1, 1.0 and 10 μg/ml histamine (Fig. 3A) . In P815 cells, induced upregulation of TLR3 was found after 6 h incubation with 10 μg/ml histamine, and after 16 h incubation with 0.1, 1.0 and 10 μg/ml histamine (Fig. 3B) . Approximately, 2-fold upregulated expression of TLR3 was observed when HMC-1 and P815 cells were incubated with 10 μg/ml of histamine for 16 h.
Inhibition of histamine-induced expression of TLR3 by anti-histamine drugs
After a 1 h incubation period, histamine H1 receptor antagonist terfenadine at 1.0 μg/ml was able to block histamine induced upregulation of TLR3 expression in HMC-1 and P815 cells. The results showed that terfenadine at 1.0 μg/ml could block histamine upregulated of TLR3 mRNA expression in mast cells (Fig. 4A) . Flow cytometry analysis also showed that terfenadine reduced histamine stimulated upregulation of TLR3 expression by 61 % and 82.9 % in HMC-1 and P815 cells, respectively (Fig. 4B) .
However, histamine H2 receptor antagonist cimenidine had low effect on blocking histamine induced TLR3 upregulation expression (Fig. 4) .
Effect of histamine on MCP-1 and IL-13 secretion from mast cells
It was found that histamine at 1.0 and 10 μg/ml induced a concentration dependent secretion of IL-13 and MCP-1 release from mast cells following 16 h incubation period. Approximately up to 2.2 and 2.6 fold of IL-13 releases were achieved when HMC-1 and P815 cells were incubated with 10 μg/ Fig. 5A and 5B). After 1 h incubation period, terfenadine was able to block histamine induced IL-13 secretion (Fig. 5A and 5B). Similarly, histamine at 10 μg/ml induced (Fig. 5C and 5D ). After 1 h incubation period, terfenadine was able to block histamine induced MCP-1 and IL-13 secretion (Fig. 5C and 5D ). However, histamine H2 receptor antagonist cimenidine had low effect on blocking histamine induced MCP-1 and IL-13 secretion (data not shown).
To determine the effect of synthetic dsRNA analogue poly (I:C) stimulation on MCP-1 and IL-13 release after histamine challenge, mast cells were preincubated with 0.1 μg/ml of histamine for 16 h before adding 25μg/ml poly (I:C) for 16 h. The results showed that histamine was able to enhance the response of HMC-1 and P815 mast cells to poly (I:C) (Fig.  5) .
Effect of cell signaling inhibitors on histamine induced release of MCP-1 and IL-13 and expression of TLR3
We employed LY294002 (PI3K/Akt inhibitor), U0126 (a selective inhibitor of MEK1/2 and thus a MAPK pathway inhibitor), SB203580 (a selective inhibitor of p38 MAPK), and AG490 (a JAK/STAT3 pathway inhibitor) to further investigate the potential histamine signaling pathways in HMC-1 and P815 cells.
U0126 and LY294002 diminished histamine induced secretion of IL-13 released by 81 %, 78.5 % from HMC-1 cells (Fig. 6A ) and 78.3 % ,73.1 % from P815 cells (Fig. 6B) , respectively, when they were pre-incubated with the cells for 30 min, indicating that reduction of IL-13 released by histamine occurs through activation of PI3K/Akt and Erk1/2/ MAPK signaling pathways. However, U0126, not LY294002, diminished histamine induced secretion of MCP-1 released both in HMC-1 and P815 cells (Fig. 6C and 6D ), indicating that reduction of MCP-1 released by histamine occurred through activation of Erk1/2/ MAPK signaling pathways. In contrast, SB203580 and AG490 had little influence on histamine induced reduction of IL-13 Similarly, U0126 and LY294002 also eliminated histamine induced upregulation of TLR3 expression up to 70.3 %, 76.5 % in HMC-1 cells (Fig. 6E) , and 63.2 %, 64.2 % in P815 cells (Fig. 6F ), respectively. All tested inhibitors did not significantly affect basal TLR3 expression in P815 cells.
Inhibition of histamine induced phosphorylation of ERK and PI3K by signaling inhibitors
U0126 inhibited approximately up to 50 and 46.7 % of histamine induced phosphorylation of ERK in HMC-1 and P815 cells, respectively at 2 h following incubation (Fig. 7A) . LY294002 diminished histamine induced phosphorylation of Akt by approximately 76.2 % and 50 % in HMC-1 and P815 cells at 2 h following incubation (Fig. 7B ). U0126 and LY294002 also inhibited basal phosphorylation of ERK (Fig. 7A) and Akt (Fig. 7B ) at 2 h following incubation.
Discussion
In the present study, we identified for the first time that histamine, a main component released from mast cells after activation, is able to upregulate the expression of TLR3, and to provoke MCP-1 and IL-13 release from human and mouse mast cells.
Although mast cells are best known for their role in allergic diseases, a series of evidence have highlighted the important roles these cells have in the protection against infection. Members of the TLR superfamily have been the most prominent in performing this function. As the main TLR related to the viral recognition, TLR3 have shown the ability to respond to viral RNAs of selected species, thus leading to production of many cytokines that are critical for regulation of many immunological functions [13] . It has been documented that TLR3 transcript is found in LAD, HMC-1, and P815 cell lines, as well as in BMMCs, HCMCs and mature tissue mast cells [8] . In the present study, we also confirmed that both human mast As the main component released from mast cell activation, histamine has been comprehensively studied as an inflammatory mediator that acts in vascular dilation, smooth muscle contraction, and gastric acid secretion. Nevertheless, little is known about the effect the histamine has on mast cells themselves. Our results demonstrated that histamine could induce upregulation of TLR3 mRNA and protein expression both in HMC-1, and P815 cell lines. LY294002, a PI3K/Akt inhibitor and U0126, a selective inhibitor of MEK1/2 could eliminate histamine induced upregulation of TLR3 expression in HMC-1 and P815 mast cells, respectively, which implies that upregulation of TLR3 expression by histamine occurs through activation of PI3K/Akt [21] and Erk1/2/ MAPK signaling pathways [22] . Moreover, histamine H1 receptor antagonist terfenadine was able to block histamine induced upregulation of TLR3 mRNA and protein expression in HMC-1 and P815 mast cell. However, histamine H2 receptor antagonist cimenidine had little effect on blocking the expression of histamine induced TLR3 upregulation. It implied that histamine induced upregulation of TLR3 expression in mast cells was conducted by the H1 receptor, as opposed to H2 receptor. The same phenomenon was found in pulmonary epithelial cells. Histamine could upregulate the TLR3 expression in A549 and NCI-H292 cells by H1 receptor [18] .
Mast cell secreted cytokines have a pivotal role in the pathogenesis of allergic disease and inflammation [23, 24] . Interleukin-13 (IL-13) and monocyte chemoattractant protein 1 (MCP-1) are two cytokines among those produced by human and mouse mast cells. IL-13 is emerging as an important mediator in the development of Th2 cell responses, which can induce IgE secretion from activated human B cells [25] . MCP-1 has a significant role in allergic responses because of its ability to induce mast cell activation and leukotriene C4 release into the airways through its receptor CCR2, which directly induces airway hyperresponsiveness [26] . Our results revealed that histamine could induce the secretion of IL-13 and MCP-1 from both human and mouse mast cell lines in a concentration dependent manner. Terfenadine, unluke cimenidine, revealed the ability to block histamine induced MCP-1 and IL-13 secretion. It implied that histamine induced secretion of IL-13 and MCP-1 from mast cells was conducted by the H1 receptor, and not H2 receptor. Moreover, U0126 and LY294002 diminished histamine induced secretion of IL-13 release from HMC-1 and P815 mast cells, indicating that reduction of IL-13 release by histamine occured through activation of PI3K/Akt [21] and Erk1/2/ MAPK signaling pathways [22] . However, U0126, and not LY294002, diminished histamine induced secretion of MCP-1 release, indicating that reduction of MCP-1 release by histamine occured through activation of Erk1/2/ MAPK signaling pathways.
Paralleling TLR3 upregulation, release of IL-13/MCP-1 was also increased by histamine via H1 receptor. Mast cells are known to produce IL-13 and MCP-1 following FcεRI aggregation, or in response to other stimuli. It remains unknown whether there is any interaction between TLR3 and IL-13/MCP-1. Nonetheless, it has been reported that various TLR activators failed to induce any kind of significant IL-13 production [27] while they significantly released MCP-1 [28] from mast cells. Therefore, the interaction between TLR3 and IL-13/MCP-1 needs to be further investigated.
It is known that poly(I:C) can activate TLR3 in human and murine cells [29] . Accordingly, we stimulated both HMC-1 and P815 cells with poly(I:C) after histamine challenge. We found that the release of MCP-1 and IL-13 by mast cells was more pronounced compared to any single stimulus (histamine or poly I:C). The observed effect indicated that histamine could synergize with TLR3 thus enhancing the release of inflammatory mediators from mast cell in addition to upregulating the expression of TLR3, which indicates that histamine may have a role in anti-infection immunity associated with TLR3. The mechanism underlying the interaction between these pass-ways has not been analyzed.
Histamine is an important mediator in the inflammatory and allergic diseases. It contributes to the progression of allergic inflammatory responses by enhancing the secretion of pro-inflammatory cytokines like IL-1β, IL-6 as well as chemokines such as IL-8 and RANTES in inflammatory cells and local tissues [30, 31] . In our study, we found that mast cell lines all express TLR3. It has been shown that histamine could induce upregulation of TLR3 expressed both in HMC-1 and P815 cell lines via H1 receptors. Histamine also induces the secretion of IL-13 and MCP-1 from both human and mouse mast cell lines in a concentration dependent manner, which can be enhanced by TLR3 ligands such as synthetic dsRNA analogue poly(I:C). We also demonstrated that the PI3K/Akt and Erk1/2/ MAPK signaling pathways are involved in histamine -mediated regulation of TLR3 expression and cytokines secretion. Accordingly, TLRs have an important role in innate immunity recognizing specific, nonself and conserved components shared by different pathogens. Our results imply there is a new mechanism for the histamine not only in allergic response, but also in anti-infection immunity.
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